Inhibiting Thrombin can Protect Against Dangerous Newborn Digestive Disease

Inhibiting the inflammatory and blood-clotting molecule thrombin with targeted nanotherapy could protect against Necrotizing enterocolitis (NEC)-like injury in newborn, reports a new mice study. The findings of the study are published in the journal Proceedings of National Academy of Sciences.

Necrotizing enterocolitis is a rare inflammatory bowel disease in which the exact cause remains unclear, and there is no effective treatment. No test can definitively diagnose the devastating condition early, so infants with suspected NEC are carefully monitored and administered supportive care, such as IV fluids and nutrition, and antibiotics to fight infection caused by bacteria invading the gut wall. Surgery must be done to excise damaged intestinal tissue if the condition worsens.

Enterocolitis - Symptoms, Causes, Diagnosis, Treatment & Prevention
Enterocolitis is referred to as inflammation of the small intestine as well as the colon. It affects both adults and children but infants are most commonly affected.

‘Necrotizing enterocolitis, a rare inflammatory bowel disease, mainly affects premature infants and is a leading cause of death in the smallest and sickest of these patients. ’
Read More..

Tweet it Now

A new preclinical study by researchers at the University of South Florida Health (USF Health) Morsani College of Medicine and Johns Hopkins University School of Medicine offers the promise of a specific treatment for NEC, one of the most challenging diseases confronting neonatologists and pediatric surgeons.

"Our data identified the inflammatory molecule thrombin, which plays a critical role in platelet-activated blood clotting, as a potential new therapeutic target for NEC," said co-author Samuel Wickline, MD, professor of cardiovascular sciences at Morsani College of Medicine and director of the USF Health Heart Institute. "We showed that anti-thrombin nanoparticles could find, capture, and inactivate all the active thrombin in the gut, thereby preventing or reducing the small blood vessel damage and clotting that accelerates NEC."

The PNAS paper’s senior author is Akhil Maheshwari, MD, professor of pediatrics and director of neonatology at the Johns Hopkins University School of Medicine. Before joining Johns Hopkins Medicine (Baltimore) in 2018, Dr. Maheshwari’s group at USF Health was the first to demonstrate that platelet activation is an early, critical event in causing NEC, and therapeutic measures to block these platelets might be a new way to prevent or reduce intestinal injury in NEC.

Necrotising Enterocolitis-Symptoms-Treatment-Surgical Options-Risks
Medindia provides a very interesting Paediatric section for doctors

The nanotherapy platform created by Dr. Wickline and USF Health biomedical engineer Hua Pan, Ph.D., delivers high drug concentrations that specifically inhibit thrombin from forming blood clots on the intestinal blood vessel wall without suppressing the (clotting) activity needed to prevent bleeding elsewhere in the body. This localized treatment is particularly important for premature infants, Dr. Wickline said, because the underdeveloped blood vessels in their brains and other vital organs are still fragile and susceptible to rupture and to bleed.

For this study, the researchers used a model they created infant mice, or pups, induced to develop digestive tract damage resembling human NEC, including the thrombocytopenia commonly experienced by premature infants with NEC. Thrombocytopenia is characterized by low counts of blood cell fragments known as platelets, or thrombocytes, which normally stop bleeding from a cut or wound by clumping together to plug breaks injured blood vessels.

Probiotics Useful in Preventing Necrotizing Enterocolitis in Preterm Infants
Probiotics are useful in preventing a serious complication called necrotizing enterocolitis in preterm infants. Recently published guidelines suggest the use of these agents in most premature infants.

The molecule thrombin plays a key role in the bowel inflammation driven by overactive platelets. While investigating the role of platelet depletion in NEC-related thrombocytopenia, the USF-Johns Hopkins researchers were surprised to find that thrombin mediates platelet-activated blood clotting early in the pathology of NEC-like injury - before bacteria leaks from inside the gut to circulating blood or other organs. This clotting clogs small blood vessels and restricts blood flow to the inflamed bowel.

Eventually, the lining of the damaged intestinal wall can begin to die off. The investigative therapy essentially works "like a thrombin sponge" that is exponentially more potent than current agents used to inhibit clotting, Dr. Wickline explained. "It literally puts trillions of nanoparticles at that damaged (intestinal wall) site to sponge up all the overactive thrombin, which tones down the clotting and inflammation processes promoted by thrombin."

Kids with Food Protein-induced Enterocolitis More Likely to Have Other Allergies
Children with a rare food allergy have a higher chance of being diagnosed with other allergies, including eczema, traditional food allergy, and asthma.

"We are so excited about finding this new way to attenuate intestinal injury in NEC," Dr. Maheshwari said.

The same approach has also been shown in preclinical studies to inhibit the growth of atherosclerotic plaques and certain kidney injuries without causing systemic bleeding problems. Dr. Wickline added. "The nanoparticles can be tailored to other inflammatory diseases highly dependent on thrombin for their progression."

The study authors conclude that their experimental targeted treatment for NEC merits further evaluation in clinical trials.

Source-Eurekalert